Compare ESE & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESE | ERAS |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.5B |
| IPO Year | 1994 | 2021 |
| Metric | ESE | ERAS |
|---|---|---|
| Price | $309.68 | $17.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $283.33 | $12.08 |
| AVG Volume (30 Days) | 287.0K | ★ 4.8M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 193.15 | 36.23 |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $37,000,000.00 | N/A |
| Revenue This Year | $21.51 | N/A |
| Revenue Next Year | $6.91 | N/A |
| P/E Ratio | $279.49 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $145.09 | $1.06 |
| 52 Week High | $315.19 | $18.20 |
| Indicator | ESE | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 69.29 | 62.62 |
| Support Level | $198.85 | $1.57 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 10.71 | 1.03 |
| MACD | 2.96 | 0.07 |
| Stochastic Oscillator | 88.99 | 73.62 |
ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace & Defense (A&D), Utility Solutions Group (USG), and RF Test & Measurement (Test). The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.